ONCSQ (OncoSec Medical) ROCE %: -595.40% (As of Jan. 2023)


What is OncoSec Medical ROCE %?

OncoSec Medical ONCSQ -99.00% ROCE % is -595.40% as of Jan. 2023.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OncoSec Medical's annualized ROCE % for the quarter that ended in Jan. 2023 was -595.40%.

OncoSec Medical  (OTCPK:ONCSQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OncoSec Medical ROCE % Related Terms

OncoSec Medical ROCE % Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical ROCE % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -216.02 -122.78 -191.05 -138.79 -117.98

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.99 -145.12 -170.39 -282.78 -595.40

OncoSec Medical ROCE % Calculation

OncoSec Medical's annualized ROCE % for the fiscal year that ended in Jul. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jul. 2022 )  (A: Jul. 2021 )(A: Jul. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jul. 2022 )  (A: Jul. 2021 )(A: Jul. 2022 )
=-37.493/( ( (56.276 - 7.962) + (21.878 - 6.633) )/ 2 )
=-37.493/( (48.314+15.245)/ 2 )
=-37.493/31.7795
=-117.98 %

OncoSec Medical's ROCE % of for the quarter that ended in Jan. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2023 )  (Q: Oct. 2022 )(Q: Jan. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2023 )  (Q: Oct. 2022 )(Q: Jan. 2023 )
=-27.296/( ( (14.439 - 6.91) + (8.871 - 7.231) )/ 2 )
=-27.296/( ( 7.529 + 1.64 )/ 2 )
=-27.296/4.5845
=-595.40 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -595.40% mean?
OncoSec Medical (ONCSQ) has a ROCE % of -595.40% as of Jan. 2023.
Is OncoSec Medical's ROCE % too high?
OncoSec Medical's current ROCE % is -595.40%.
How does OncoSec Medical's ROCE % compare to NOVNQ and USRM?
OncoSec Medical's ROCE % of -595.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. OncoSec Medical's current ROCE % is -595.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current ROCE % of -595.40%. The current ROCE % is -595.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current ROCE % is -595.40% as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.